BrainChild Bio
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Biopharma, Cell therapy, Oncology
- Stage
- Series A
- Founders
- Michael Jensen, MD
Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands
A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
BrainChild Bio, a Seattle clinical-stage biotech led by CEO Steven Brugger, raised $116M in a Series A led by an undisclosed private family fund and foundation with participation from Seattle Children’s and WRF Capital to fund Phase 2 ILLUMINATE study of BCB‑276 for DIPG and continued development of BCB‑214 for glioblastoma.
BrainChild Bio raises $116M Series A to fund pivotal Phase II trial of B7-H3 CAR T for DIPG
BrainChild Bio closed a $116 million Series A to fund a pivotal Phase II registrational trial (ILLUMINATE, NCT07680439) of BCB-276, a B7-H3-targeted CAR T therapy for DIPG, and to advance BCB-214 toward clinical testing. The company, spun out of Seattle Children's in January 2024, reported encouraging Phase I data (median overall survival 19.8 months) and has Breakthrough Therapy and RMAT designations for BCB-276.
BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG
BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.
BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
BrainChild Bio raised $116 million in a Series A to fund a pivotal trial of a B7-H3–targeted CAR-T therapy for pediatric diffuse intrinsic pontine glioma (DIPG), aiming to make CAR-Ts function more like small molecules for brain tumors.
BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG
BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.
BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG
BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.
BrainChild Bio raises $116M to advance CAR-T treatments for pediatric brain cancers, including Phase 2 DIPG trial
BrainChild Bio raised $116 million to advance CAR-T cell therapies for rare pediatric brain cancers, with BCB-276 in Phase 2 for DIPG and BCB-214 nearing human testing for glioblastoma.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
Seattle Children’s Launches BrainChild Bio Startup to Develop CAR T-Cell Therapies for Pediatric Brain Cancer
Seattle Children’s has spun out BrainChild Bio, a biotech startup focused on developing CAR T-cell therapies for incurable pediatric brain cancers like diffuse intrinsic pontine glioma. Led by Dr. Michael Jensen, the company will operate from the Building Cure innovation hub in downtown Seattle.
People
-
Michael Jensen Founder, Founder and Chief Scientific Officer
-
Steven Brugger Executive, CEO
